Judge slashes $8 bln Risperdal award against Johnson & Johnson to $6.8 mln




  • In US
  • 2020-01-17 18:54:46Z
  • By Reuters

Jan 17 (Reuters) - A Pennsylvania judge on Friday slashed to $6.8 million from $8 billion a punitive damages award against Johnson & Johnson for allegedly failing to warn men that they could grow breasts by using its antipsychotic drug Risperdal.

The decision by Judge Kenneth Powell of the Philadelphia Court of Common Pleas to reduce punitive damages for the plaintiff Nicholas Murray followed a jury's imposition of the original award last Oct. 8.

No reason was immediately given for the reduction, which was disclosed in court records.

Murray, like other male plaintiffs in mass tort litigation over Risperdal, claimed that he developed breasts after being prescribed the medicine when he was a boy. He was 26 when the jury made the $8 billion award. (Reporting by Jonathan Stempel in New York, Editing by Rosalba O'Brien)

COMMENTS

More Related News

Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial
Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial
  • US
  • 2020-09-25 18:56:18Z

A single shot, versus a rival two-dose approach being tested by Moderna Inc and Pfizer Inc , could simplify distribution of the vaccine. The trial in close to 1,000 healthy adults, which is backed by the U.S. government, began after the J&J vaccine was found in July to offer strong protection in a single dose to monkeys.

J&J signs manufacturing deal with GRAM for potential COVID-19 vaccine
J&J signs manufacturing deal with GRAM for potential COVID-19 vaccine
  • US
  • 2020-09-25 14:05:14Z

Michigan-based GRAM will manufacture the healthcare conglomerate's SARS-CoV-2 vaccine candidate, which is being developed with part funding from the U.S. government, and provide finished vials. Earlier in the week, J&J launched a late-stage trial of its experimental single-shot COVID-19 vaccine and said its expects results of the trial by year end or early next year. J&J, which is readying its supply chain to start distribution as soon as it gets FDA's approval, expects to manufacture as many as 1 billion doses in 2021.

Lawyers eye neo-Nazi website founder
Lawyers eye neo-Nazi website founder's assets for $14M award
  • US
  • 2020-09-23 19:51:06Z

Attorneys for a Montana real estate agent are eyeing the assets of a neo-Nazi website operator to collect a $14 million court judgment against the man for an anti-Semitic online "troll storm" that he orchestrated against the Jewish woman and her family, court filings show. More than a year has passed since a federal judge in Montana entered a default judgment against Andrew Anglin, the Daily Stormer's founder and publisher. Plaintiffs' lawyers say the Ohio native has failed to pay any of the monetary award to Tanya Gersh.

Coronavirus updates: J&J begins late-stage trial for single-shot vaccine; Ginsburg public viewing to be held outside Supreme Court
Coronavirus updates: J&J begins late-stage trial for single-shot vaccine; Ginsburg public viewing to be held outside Supreme Court

Miami-Dade County schools will return to in-person instruction beginning Oct. 14. Donald Trump says U.S. death toll is "a shame." Latest COVID news.

Late-stage study of first single-shot vaccine begins in US
Late-stage study of first single-shot vaccine begins in US
  • World
  • 2020-09-23 10:46:56Z

Johnson & Johnson is beginning a huge final study to try to prove if a single-dose COVID-19 vaccine can protect against the virus. The study starting Wednesday will be one of the world's largest coronavirus vaccine studies so far, testing the shot in 60,000 volunteers in the U.S., South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru. A handful of other vaccines in the U.S. - including shots made by Moderna Inc. and Pfizer Inc. - and others in other countries are already in final-stage testing.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US